Recombinant Human EphA7/EHK3 Protein (His & GST Tag)

SKU: PKSH030354

Size: 50μg

Storage: Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.

Shipping: This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at < - 20°C.

Exp date: 12 months

Category ID_II: Recombinant Proteins

Category ID_III: Others

Abbreviation:

Target Synonym: EHK-3;EHK3;EK11;EPH Homology Kinase 3;EPH-Like Kinase 11;EPHA7;Ephrin Type-A Receptor 7;HEK11;hEK11

Research Areas: Cardiovascular;Neuroscience

Conjugation:

Target Species: Human

Expression Host: Baculovirus-Insect Cells

Application: Enzyme

Fusion tag: N-His-GST

UNIProt ID: Q15375

Accession: NP_004431

Background: Ephrin type-A receptor 7, also known as EphA7, belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family which 16 known receptors (14 found in mammals) are involved: EPHA1, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHA9, EPHA10, EPHB1, EPHB2, EPHB3, EPHB4, EPHB5, EPHB6. The Eph family of receptor tyrosine kinases (comprising EphA and EphB receptors) has been implicated in synapse formation and the regulation of synaptic function and plasticity6. Eph receptor-mediated signaling, which is triggered by ephrins7, probably modifies the properties of synapses during synaptic activation and remodeling. Ephrin receptors are components of cell signalling pathways involved in animal growth and development, forming the largest sub-family of receptor tyrosine kinases (RTKs). Ligand-mediated activation of Ephs induce various important downstream effects and Eph receptors have been studied for their potential roles in the development of cancer. Down-regulation of EphA7 secondary to hypermethylation has been reported in colorectal cancer. The expression of EphA7 was reduced in all tested gastric cancer cell lines; however, there is marked variability in expression among gastric carcinoma specimens. EphA7 may have roles in the pathogenesis and development of gastric carcinomas.

Concentration:

Activity: The specific activity was determined to be 9.5 nmol/min/mg using Poly(Glu:Tyr) 4:1 as substrate.

Sequence: Gly579-Val998

Purity: > 94 % as determined by reducing SDS-PAGE.

Formulation: Supplied as sterile solution of 20mM Tris, 500mM NaCl, pH 8.0, 10% glycerol

Reconstitution: Not Applicable

Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.

Calculated MW: 75.2 kDa

ObservedMW: 76 kDa